Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews frontal fibrosing alopecia, exploring its characteristics, demographics, and associated conditions, and calls for controlled trials due to an increase in worldwide cases; it reports no new findings.

This review discusses various dermatological scoring systems used to objectively assess disease severity and guide treatment decisions, reporting no new clinical results.

In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.

This review summarizes the current treatment modalities for frontal fibrosing alopecia and provides a practical guide for clinicians, but reports no new clinical results.

This review article examines the current understanding of frontal fibrosing alopecia, noting its prevalence in different demographics and the roles of genetic and environmental factors in its pathogenesis, while highlighting that treatment approaches remain varied and lack standardization.

This study reported that diffuse lichen planopilaris significantly impairs quality of life in Moroccan patients, with trichodynia and hair quality changes most affecting daily functioning and leisure activities.

This integrative literature review found that hydroxychloroquine may stabilize inflammatory scarring autoimmune alopecias like frontal fibrosing alopecia, especially when combined with other therapies, while its effectiveness in non-scarring alopecias appears inconsistent and is limited to refractory cases.

This study reviewed the use of microinfusion of microparticles (MMP®) with methotrexate for treating alopecia frontal fibrosante and found it reduced symptoms associated with the condition and improved specific scalp measurements, showing that the technique is safe and well-tolerated.

This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.

This review concluded that oral tofacitinib and adalimumab are promising treatments for cicatricial alopecia, showing effectiveness in improving signs and symptoms but requiring regular monitoring for adverse effects. The authors emphasize the need for further extensive studies to solidify these findings.

This study found a significant discordance between clinical symptoms and dermatoscopic signs with histopathological inflammation in patients with LPP and AFF, affecting diagnostic and therapeutic approaches.

This study reports that frontal fibrosing alopecia in Brazilian patients is common in postmenopausal women and often associated with hypothyroidism and facial irritation from cosmetic products.

This review found that antimalarial agents were more effective than steroids for Lichen planopilaris, while finasteride and dutasteride showed favorable impacts on frontal fibrosing alopecia, despite heterogeneous study quality.

This review discusses the evolving understanding of frontal fibrosing alopecia as a generalized skin condition with diverse manifestations, and reports no new clinical results.

This phase 2a trial evaluated Samcyprone for common wart treatment and found that while a sensitization reaction is necessary for therapeutic response, its level does not predict wart clearance.

Lichen planopilaris and frontal fibrosing alopecia are likely the same disease with different clinical appearances.

Lichen planopilaris is a rare, chronic condition causing hair loss, mainly in middle-aged women, and early treatment is important to prevent permanent baldness.

In this study, a patient with lichen planopillaris experienced complete resolution of itching and hair shedding following treatment with a new platelet-rich plasma regimen, marking the first reported success in this context.

This article reviews lichen planopilaris, its presentation, and treatment challenges, and emphasizes the need for more research into its pathogenesis and therapy efficacy; it reports no new findings.

In a study reviewing 291 patients with lichen planopilaris, findings revealed that women were more commonly affected than men, cyclosporine and methotrexate were most effective in achieving remission, and 5-alpha reductase inhibitors and systemic retinoids were particularly beneficial for frontal fibrosing alopecia.

Recognizing IPPP is crucial to prevent misdiagnosis and unnecessary treatments.

This case report highlights a misdiagnosis of traction alopecia that progressed to lichen planopilaris in a patient of color, emphasizing the need to consider LPP in similar cases due to differing treatments.

In this case report, a 65-year-old woman with lichen planopilaris achieved stabilization of her condition through early recognition and systemic corticosteroid therapy, emphasizing the critical role of coordinated management between primary care and dermatology.

This study reported that four patients with lichen planopilaris showed dramatic improvement, including symptom reduction and hair regrowth, after treatment with low-level light therapy.

This study suggests that although data on JAK inhibitors for treating LPP and FFA is mainly from retrospective studies and case reports, these inhibitors may offer a new treatment option, particularly for challenging cases.

This study found diverse clinical presentations of lichen planopilaris, with classic lichen planopilaris being the most common, highlighting the importance of recognizing this variability for accurate diagnosis.

This review summarizes the roles of Wnt signaling in wound healing but presents no new clinical findings, suggesting potential for Wnt-based therapies to enhance tissue regeneration.

This review discusses the potential causes and treatments for frontal fibrosing alopecia but reports no new clinical findings, highlighting the need for further research to understand its pathogenesis and develop validated treatments.

This review compiles existing data on frontal fibrosing alopecia and highlights the promise of 5-alpha reductase inhibitors as a treatment option, while noting the need for clarity on its cause and progression.

This review discusses clinical presentations and interventions for alopecia in women of color, highlighting the importance of early recognition and treatment but providing no new clinical results.